LETTERS TO THE EDITOR

Lag time for children with brain tumours

We read with considerable interest the paper by Edgeworth et al highlighting the failure of physicians to recognise often vague symptoms and/or signs as markers of serious disease, especially childhood brain tumours.1 We previously studied the time interval (designated lag time) between the first symptom and/or signs and confirmed diagnosis in an unselected cohort of children with cancer including 28 with brain tumours, and found that for brain tumours the lag time of 13 weeks far exceeded the interval for all other tumours (5 weeks for acute lymphoblastic leukaemia, bone tumours 8.4 weeks, nephroblastoma 2.8 weeks). There have been two other published series on lag time in brain tumours of childhood. Flores et al in Atlanta found a symptom interval of 26 weeks for 79 children. Only 38% of the brain tumour patients were diagnosed within one month of symptom onset compared with 84% for those with renal tumours, and 80% for childhood leukaemia.

Pollock et al in St Louis reported a lag time of 9.4 weeks for 380 children with a variety of brain tumours.2 The site of tumour and histological type does appear to affect lag time. Flores et al noted mean lag times of 43.4 and 10.8 weeks respectively for supratentorial and infratentorial tumours and also shorter lag times for those with more marked symptoms and signs. Two of these series have reported that younger patients present earlier.3 It has been argued that even with vague symptoms and signs, younger children are both more likely to be brought to medical attention because of parental anxiety or in any case are being seen more regularly for other routine health surveillance purposes (for example vaccinations). Self reporting in older children and adolescents is more of a 'hit and miss' process. Despite these findings our south east Scotland study failed to show any influence of length of lag time on clinical outcome.6 Edgeworth et al have essentially assessed one component of lag time, namely the time for doctors to recognise the significance of signs or symptoms once a child is brought to their attention.7 Incorrect diagnosis will produce a delay in the amount of parent and patient anxiety let alone resentment. Ongoing medical education must be programmed to try to prevent such delays. However, for the majority of children the other components, namely the time from first symptom or sign to when medical advice is sought, and the time to get through the system and receive appropriate treatment may play a role. The apparent relationship to inherent tumour characteristics and health care provision respectively, to make the major contribution to length of lag time. We are conducting a prospective study attempting to clarify the contribution of each of these components to the overall lag time. From all the published work to date the greatest contribution does appear to be related to inherent tumour characteristic which in turn determine the mode of presentation. Before parents blame themselves or doctors for delayed diagnosis we need to emphasise these other aspects of tumour presentation.

O B EDEN
Christie Hospital NHS Trust,
Williams Road, Wihkinson,
Manchester M20 4BX

V SAHA
Department of Paediatric Oncology,
St Bartholomew's Hospital
West Smithfield,
London EC1A 7BE

Is microalbuminuria progressive?

We read with interest the article by Shields et al on the question whether microalbuminuria is progressive or not.1 Our data, presented at the 21th Annual Meeting of the ISPAD in Linköping, are fully in line with the conclusions of this work. In 1984 we identified 14 children and adolescents as having persistent microalbuminuria (urinary albumin excretion (UAE) 30–300 mg/day) with insulin dependent diabetes mellitus (median age = 15.2 years; median duration of diabetes = 5.7 years). Eight cases showed HLA DR3-DR4. A regular follow up for six years of these microalbuminuric patients allowed us to follow their progression: two developed macroalbuminuria, five remained microalbuminuric without presenting a significant increase in UAE, and seven remained stably normal, after a period of microalbuminuria of between 1 and 5.5 years. These latter patients did not differ from those remaining microalbuminuric either as regards degree of metabolic control or UAE levels during follow up, whereas they did differ as regards a higher prevalence (6/7) of cases with onset of diabetes in peripubertal age. Shield et al did not report data regarding age or pubertal stage of the single microalbuminuric patients; we feel this finding could be important in that it could be the pubertal factor which differentiates the natural history for microalbuminuria in childhood from that of adulthood. Puberty, with its important hormonal changes, could in fact act as 'exercise test' for the kidney of predisposed subjects; this would lead to a deterioration which, limited to the pubertal period, would be temporary. Supporting this hypothesis is the fact that six of our 10 patients (all females) with intermitent microalbuminuria, occurring at the beginning of puberty, reverted to normal at the end of puberty itself, that is after menarche.

The predictive value for later overt nephropathy, microalbuminuria is therefore poor among children and young adults and this possible spontaneous normalisation of microalbuminuria should be taken into account when evaluating the effects of interventional drug treatment in patients of this age.

SILVANA SALARDI
EMANUELE CACCIARI
Fiera Paediatric Clinic,
University of Bologna,
Via Massarenti 11,
40138 Bologna, Italy

Dr Shield comments:

This report is now the third to challenge the predictive value of microalbuminuria defined as 20–200 μg/min (30–300 mg/day) in childhood and adolescence as a recent article from Rudberg and Dahlquist reached similar conclusions.2 The implications of microalbuminuria in this age group need to be addressed prospectively in a large cohort of patients before embarking on either routine clinical screening or interventional trials. A study (microalbuminuria in diabetic adolescents and children, MIDAC), currently in the pilot stage, will address the prevalence and progression of abnormal albumin excretion in approximately 2000 children, with its relationship with glycaemic control, blood pressure, and pubertal status which we agree may be of importance in defining the longer term implications of microalbuminuria.


Mycoplasma infection and Kawasaki disease

We report for the first time a case of mycoplasma infection complicated by Kawasaki disease, and discuss possible mechanisms.

A 6 year old boy presented with two days of sore throat, fever, vomiting, and abdominal pain. Examination revealed pharyngitis and cervical lymphadenopathy. Jaundice and tender hepatomegaly developed the next day. Investigations revealed a leucocytosis (white cell count 18.7 × 10⁹/l), deranged liver function (bilirubin concentration 73 μmol/l, alanine transaminase activity 316 units/l), and positive immunofluorescence for IgM to Mycoplasma pneumoniae, with a fourfold rise in antibody titre to greater than 256. Testing for other causes of hepatitis was negative. Mycoplasma hepatitis was diagnosed, and treatment with azithromycin started.

His fever persisted, and bilateral conjunctivitis, raised erythrocyte sedimentation rate (ESR) (maximum 125 mm/hour), thrombocytosis (maximum 846 × 10⁹/l) on day 9, dis tended gall bladder on ultrasound scan on day 11 and periungual desquamation developed on day 17. A 17 day cardiac ultrasound examination was normal.

Kawasaki disease was diagnosed, based on the persistent fever, pharyngitis, cervical lymphadenopathy, bilateral conjunctivitis, raised ESR, thrombocytosis, and periungual desquamation. A distended gall bladder on ultrasound scan is found in 3% of patients with Kawasaki disease.3 Treatment with intravenous

1996;71:266–267

266

Archives of Disease in Childhood

group.bmj.com on June 16, 2017 - Published by http://adc.bmj.com/
Downloaded from
Is microalbuminuria progressive?

S Salardi and E Cacciari

Arch Dis Child 1996 75: 266
doi: 10.1136/adc.75.3.266-a

Updated information and services can be found at:
http://adc.bmj.com/content/75/3/266.2.citation

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/